Pharmacapsules @ Gowlings - August 27, 2008.Edited by Adrienne Blanchard and Jane B.H. Steiberg Contents Creation of Disease Specific Stem Cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young for Ten Diseases Announced A New Way to Study Cancer 2008 World Patent Report Released by WIPO WIPO World Intellectual Property Organization WIPO World Intellectual Piracy Organization (satire website) WIPO Write in Poll Option WIPO Wing Information Protection Office (USAF) Recent Cases Creation Of Disease Specific Stem Cells For Ten Diseases Announced By: Natalie de Paulsen On August 7, 2008 the article Disease-Specific Induced Pluripotent Stem Cells which details the creation of stem cells from patients with ten different genetic diseases, was published in the on-line version of Cell. In this article, the authors describe the generation of induced pluripotent plu·rip·o·tent or plu·ri·po·ten·tial adj. 1. Capable of affecting more than one organ or tissue. 2. Not fixed as to potential development. Used of an embryonic cell. stem (iPS) cells from patients with the following diseases: Adenosine deaminase adenosine deaminase /aden·o·sine de·am·i·nase/ (ADA) (de-am´i-nas) an enzyme that catalyzes the hydrolytic deamination of adenosine to form inosine, a reaction of purine metabolism. deficiency-related severe combined immunodeficiency Severe Combined Immunodeficiency Definition Severe combined immunodeficiency (SCID) is the most serious human immunodeficiency disorder(s). It is a group of congenital disorders in which both the humoral part of the patient's immune system and the cells (ADA-SCID Noun 1. ADA-SCID - SCID resulting from mutation of a gene that codes for adenosine deaminase SCID, severe combined immunodeficiency, severe combined immunodeficiency disease - a congenital disease affecting T cells that can result from a mutation in any one of ) Shwachman-Bodian-Diamond syndrome (SBDS SBDS Shwachman-Bodian-Diamond Syndrome (gene) SBDS Simulation-Based Design System ) Gaucher disease Gaucher Disease Definition Gaucher disease is a rare genetic disorder that results in accumulation of fatty molecules called cerebrosides. It can have serious effects on numerous body organs including the liver, spleen, bones and central nervous system. (GD) type III Duchenne muscular dystrophy Duchenne muscular dystrophy (DMD) The most severe form of muscular dystrophy, DMD usually affects young boys and causes progressive muscle weakness, usually beginning in the legs. (DMD (1) (Digital Micromirror Device) See DLP. (2) (Digital Multi-layer Disk) See high-def DVD formats. ) and Becker muscular dystrophy Beck·er muscular dystrophy n. A form of pseudohypertrophic muscular dystrophy that is less severe than Duchenne's muscular dystrophy, in which patients remain ambulatory and usually live until the third or fourth decade. (BMD BMD In currencies, this is the abbreviation for the Bermudian Dollar. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. ) Parkinson disease Huntington disease (HD) Juvenile-onset, type 1 diabetes mellitus type 1 diabetes mellitus Brittle DM, insulin-dependent DM, juvenile-onset DM Endocrinology A severe form of DM caused by ↓ endogenous insulin production by the pancreas, which comprises +– 10% of DM Clinical Extreme hyperglycemia, lability of glucose (JDM JDM Japanese Domestic Market JDM Judgment and Decision Making JDM Juvenile Dermatomyositis (Childhood immune disease affecting skin and muscles) JDM Justin Downey Marketing (Irving, TX) ) Down syndrome (DS)/trisomy 21 and Carrier state of Lesch-Nyhan syndrome. The study's corresponding author, George Daley states: "Researchers have long wanted to find a way to move a patient's disease into the test tube, to develop cells that could be cultured into the many tissues relevant to diseases of the blood, the brain, and the heart, for example. Now, we have a way to do just that --- to derive pluripotent cells from patients with disease, which means the cells can make any tissue and can grow forever." Being able to work with the cells in test tubes will facilitate investigation of the diseases and allow others around the world to do so as well. The authors have confirmed that the stem cell lines developed will be made available to scientists worldwide. For more information, please see the link to the abstract and article Disease-Specific Induced Pluripotent Stem Cells by In-Hyun Park et al. at http://www.cell.com/content/article/abstract?uid=PIIS PIIS Posterior Inferior Iliac Spine 0092867408010015 and the summary article Scientists Create Disease-Specific Stem Cell Lines by Catharine Paddock at http://www.medicalnewstoday.com/articles/117597.php. A New Way To Study Cancer By: Natalie Rizkalla-Kamel A team of researchers in Calgary have developed new research techniques for studying cancer. They have presented a new way to grow an atypical teratoid/rhabdoid tumour (brain cancer found in children), which involves adding brain fluid to the cancer cells in a Petri dish, simulating their natural growing environment. This method is a deviation from traditional methods of growing specimens for cancer research, which includes growing tumours in animals and harvesting them later to be studied or trying to grow them in a culture rich with nutrients. A result of this study is that now researchers have an endless supply of cell lines for this type of cancer. With this information, the research team tested a new drug called AEW-541 specifically designed to inhibit the growth of this type of cell. It is hoped that this new research method can be applied to other forms of cancer, although its too early to predict the lasting effects. For more information, please see: Cancer researchers in Calgary develop new way of studying cancer http://www.cbc.ca/cp/health/080807/x080702A.html 2008 World Patent Report Released By WIPO By: Jennifer Wilkie On July 31, 2008, the World Intellectual Property Office (WIPO) released its report detailing statistics on patent filings around the world, for 2006 (the latest year for which complete statistics are available) and makes comparisons to previous years. The report shows increased a patent activity of 4.9% between 2005 and 2006, due largely to increased filings in China, Korea and the U.S. Further, statistics, among other things, show increased internationalization The support for monetary values, time and date for countries around the world. It also embraces the use of native characters and symbols in the different alphabets. See localization, i18n, Unicode and IDN. internationalization - internationalisation of patent filings, detail resident vs. non-resident filings, and show details as to the number of filings by subject matter. For example, pharmaceutical filings were up a modest 1.7% and biotechnology filings were down 2.7%. For more information, please see: The full report: World Patent Report: A Statistical Review (2008) http://www.wipo.int/export/sites/www/ipstats/en/statistics/patents/pdf/wipo_pub_931.pdf Recent Cases By: Beverley Moore Canada v. Abbott; appeal of a listing decision; July 25, 2008; lansoprazole The Court of Appeal overturned the trial judge and upheld the decision of the Minister to remove a patent from the Patent Register. The Court of Appeal held that under the amended Regulations, in order to be listed on the Patent Register, the patent must contain a claim to the changed use in the SNDS SNDS Sudden Northwood Death Syndrome SNDS Stock Number Data Section . Even though the changed use may come within the claims of the patent, it must specifically claim the changed use, and not the original use of the medicine. The expert evidence went no farther than showing that the patent would have been eligible for listing against the original submission if the date of the submission had not preceded the date of the patent application. The Court of Appeal concluded stating that to allow the listing of the patent for a changed use which was not the subject of a specific claim would undo the reform which the amended Regulations seek to introduce. The full text of the decision can be found at: http://decisions.fca-caf.gc.ca/en/2008/2008fca244/2008fca244.html Abbott v. Apotex; motion to dismiss under Section 6(5)(a); July 29, 2008; lansoprazole In a decision made with respect to a patent listed under the old Regulations, prior to the amendments, the Court found that the patent only claims a delivery system or a means of enhancing a delivery system. Thus, it does not include a claim for the medicine itself and is not eligible for listing on the Patent Register. Full text of the decision can be found at: http://decisions.fct-cf.gc.ca/en/2008/2008fc919/2008fc919.html Apotex v. Executive Officer for the Ontario Public Drugs Programs; judicial review; August 6, 2008; perindopril The Court dismissed Apotex' judicial review of the Executive Officer of the Ontario Public Drugs Programs (EO) decision refusing to list Apo-perindopril at 85% of the price of the original brand name product. The Court held that the general rule is that generic drugs are to be listed at 50% or less of the price of the original brand drug. However, the EO has discretion to negotiate an agreement with the generic price for a higher price. In this case, Apotex requested a higher price on the basis that even at 85%, there would be significant savings to the government and furthermore, as it was involved in patent infringement litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , such a price was necessary to cover the cost of its legal defence. The Court held that the EO was open to negotiation, but Apotex' rationale was not helpful to that negotiation. The statement that 85% is better than nothing is simply stating the obvious. Furthermore, while litigation is ongoing, there can be no rational basis for the government to back one of the litigants by giving special consideration and pricing to offset litigation costs. In addition, Apotex' suggestion that the government indemnify Apotex if it is ordered to pay damages to Servier is irrational. Thus, it was not surprising that the EO declined to exercise discretion in favour of a higher price for Apotex' drug. She was provided with no good reason for doing so. Full text of the decision can be found at: http://www.canlii.org/en/on/onscdc/doc/2008/2008canlii39429/2008canlii39429.pdf The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances. Ms Adrienne Blanchard Gowling Lafleur Henderson LLP LLP - Lower Layer Protocol Suite 1600, 1 First Canadian Place First Canadian Place is a skyscraper in Toronto, Ontario, Canada. At 298 metres, or 978 feet (355 metres with antenna included), it is Canada's tallest skyscraper and the eleventh tallest building in North America. 100 King Street West Toronto Ontario M5X 1G5 CANADA E-mail: info@gowlings.com Click Here for related articles (c) Mondaq Ltd, 2008 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion